MAdCAM costimulation through Integrin-α4β7 promotes HIV replication
Autor: | Elena Martinelli, Claudia Cicala, Jocelyn C Ray, Marcelo A. Soares, James Arthos, Donald Van Ryk, Mark Connors, Mia Waliszewski, Joseph Hiatt, Danlan Wei, Francois Villinger, Aftab A. Ansari, Ian Perrone, Fatima Nawaz, Stephen A. Migueles, Alia Sajani, Ronke Olowojesiku, Anthony S. Fauci, Katija Jelicic, Livia R. Goes |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Immunology High endothelial venules Integrin Retinoic acid Biology 3. Good health 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology chemistry Viral replication Downregulation and upregulation Monoclonal Addressin biology.protein Cancer research Immunology and Allergy Antibody |
Zdroj: | Mucosal Immunology. 11:1342-1351 |
ISSN: | 1933-0219 |
Popis: | Human gut-associated lymphoid tissues (GALT) play a key role in the acute phase of HIV infection. The propensity of HIV to replicate in these tissues, however, is not fully understood. Access and migration of naive and memory CD4+ T cells to these sites is mediated by interactions between integrin α4β7, expressed on CD4+ T cells, and MAdCAM, expressed on high endothelial venules. We report here that MAdCAM delivers a potent costimulatory signal to naive and memory CD4+ T cells following ligation with α4β7. Such costimulation promotes high levels of HIV replication. An anti-α4β7 mAb that prevents mucosal transmission of SIV blocks MAdCAM signaling through α4β7 and MAdCAM-dependent viral replication. MAdCAM costimulation of memory CD4+ T cells is sufficient to drive cellular proliferation and the upregulation of CCR5, while naive CD4+ T cells require both MAdCAM and retinoic acid to achieve the same response. The pairing of MAdCAM and retinoic acid is unique to the GALT, leading us to propose that HIV replication in these sites is facilitated by MAdCAM-α4β7 interactions. Moreover, complete inhibition of MAdCAM signaling by an anti-α4β7 mAb, an analog of the clinically approved therapeutic vedolizumab, highlights the potential of such agents to control acute HIV infection. |
Databáze: | OpenAIRE |
Externí odkaz: |